JP2023552773A5 - - Google Patents

Info

Publication number
JP2023552773A5
JP2023552773A5 JP2023534128A JP2023534128A JP2023552773A5 JP 2023552773 A5 JP2023552773 A5 JP 2023552773A5 JP 2023534128 A JP2023534128 A JP 2023534128A JP 2023534128 A JP2023534128 A JP 2023534128A JP 2023552773 A5 JP2023552773 A5 JP 2023552773A5
Authority
JP
Japan
Prior art keywords
car
pharmaceutical composition
cells
inflammation
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534128A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552773A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/061794 external-priority patent/WO2022120160A1/en
Publication of JP2023552773A publication Critical patent/JP2023552773A/ja
Publication of JP2023552773A5 publication Critical patent/JP2023552773A5/ja
Pending legal-status Critical Current

Links

JP2023534128A 2020-12-04 2021-12-03 炎症関連可溶性因子の阻害剤と組み合わせたキメラ抗原受容体（ｃａｒ）ｔ細胞療法の使用 Pending JP2023552773A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063121716P 2020-12-04 2020-12-04
US63/121,716 2020-12-04
PCT/US2021/061794 WO2022120160A1 (en) 2020-12-04 2021-12-03 Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors

Publications (2)

Publication Number Publication Date
JP2023552773A JP2023552773A (ja) 2023-12-19
JP2023552773A5 true JP2023552773A5 (cg-RX-API-DMAC10.html) 2024-12-09

Family

ID=80034849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534128A Pending JP2023552773A (ja) 2020-12-04 2021-12-03 炎症関連可溶性因子の阻害剤と組み合わせたキメラ抗原受容体（ｃａｒ）ｔ細胞療法の使用

Country Status (6)

Country Link
US (1) US20240016936A1 (cg-RX-API-DMAC10.html)
EP (1) EP4272002A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023552773A (cg-RX-API-DMAC10.html)
KR (1) KR20230117383A (cg-RX-API-DMAC10.html)
CN (1) CN116888474A (cg-RX-API-DMAC10.html)
WO (1) WO2022120160A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
WO2002088346A2 (en) 2001-05-01 2002-11-07 National Research Council Of Canada A system for inducible expression in eukaryotic cells
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
KR20230005428A (ko) * 2015-05-28 2023-01-09 카이트 파마 인코포레이티드 T 세포 요법을 위한 진단 방법
US9916433B2 (en) 2016-02-10 2018-03-13 ContinUse Biometrics Ltd. Condition authentication based upon temporal-spatial analysis of vibrational responsivity
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
AU2019314452B2 (en) * 2018-08-02 2022-12-08 Kite Pharma, Inc Chimeric antigen receptor therapy T cell expansion kinetics and uses thereof
EA202190624A1 (ru) * 2018-08-31 2021-06-09 Нойл-Иммьюн Байотек, Инк. Car-экспрессирующие т-клетки и car-экспрессирующий вектор
CN112955748A (zh) * 2018-10-31 2021-06-11 葛兰素史密斯克莱知识产权发展有限公司 治疗癌症的方法

Similar Documents

Publication Publication Date Title
Burns et al. found in translation: international initiatives pursuing interleukin-1 blockade for treatment of acute Kawasaki disease
CN109311983B (zh) 人源化抗clever-1抗体及其用途
KR20110014141A (ko) 염증을 치료하는 방법
US11059906B2 (en) Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
CA2418083A1 (en) Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
Zeng et al. Antibody therapies in autoimmune inflammatory myopathies: promising treatment options
JP2021517156A (ja) 潰瘍性大腸炎を治療する方法
CN102725311A (zh) 治疗发炎的方法
US20230374124A1 (en) Compositions for treatment alopecia areata, biomarkers for treatment success and, methods of use thereof
US12054549B2 (en) Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
US20240199732A1 (en) Anti-IL-27 Antibodies and Uses Thereof
CN109414502A (zh) 治疗炎症性肠病的方法
CN115947824A (zh) 突变的人源t细胞受体恒定区、t细胞受体及t细胞受体修饰的细胞及应用
KR20240004471A (ko) 결절성 양진에 대한 치료법
WO1999015200A1 (fr) COMPOSITION MEDICINALE DONT LE PRINCIPE ACTIF EST UN INHIBITEUR DE LIAISON DE gp34
US20160289319A1 (en) Anti-ccl2 antibodies for treatment of scleroderma
Yamazoe et al. Endomyocardial biopsy and magnetic resonance imaging of acute myocarditis with adult-onset still's disease
JP2006511493A (ja) 腫瘍成長及び転移を抑制するためのラミニン５ガンマ２鎖に対する抗体の使用
HK40096057A (en) Anti-herv-w envelope protein antibody for use in the treatment of psychotic diseases
HK40104999A (en) Treatments for prurigo nodularis
CN120818050A (zh) 一种抗dkk2中和单克隆抗体及其用途
JP2025530773A (ja) 結節性痒疹のための治療
Sigle Targeting Extracellular Cyclophilin A in Cardiac Extracellular Matrix Remodeling
KR20230018463A (ko) 정신 질환의 치료에 사용하기 위한 항-herv-w 엔벨로프 단백질 항체
Takatsuki et al. Pulmonary hypertension